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Abstract Campylobacter jejuni is the most prevalent cause
of a food-borne gastroenteritis in the developed world, with
poultry being the main source of infection. Campylobacter
jejuni, like other Gram-negative bacteria, constitutively re-
leases outer membrane vesicles (OMVs). OMVs are highly
immunogenic, can be taken up by mammalian cells, and are
easily modifiable by recombinant engineering. We have tested
their usefulness for an oral (in ovo) vaccination of chickens.
Four groups of 18-day-old chicken embryos (164 animals)
underwent injection of wt C. jejuni OMVs or modified
OMVs or PBS into the amniotic fluid. The OMVs modifica-
tions relied on overexpression of either a complete wt cjaA gene
or the C20A mutant that relocates to the periplasm. Fourteen
days post-hatch chicks were orally challenged with live
C. jejuni strain. Cecum colonization parameters were analyzed
by two-way ANOVAwith Tukey post-hoc test. The wtOMVs
and OMVs with wtCjaA overexpression were found to confer
significant protection of chicken against C. jejuni (p = 0.03 and
p = 0.013, respectively) in comparison to PBS controls and are
promising candidates for further in ovo vaccine development.
Keywords Campylobacter jejuni . Outer membrane
vesicles (OMV) . in ovo immunization
Introduction
Campylobacter strains are recognized as a major causal agent
of bacterial diarrhea both in developing and developed regions
of the world. Campylobacter infection rates have been in-
creasing steadily over the past decade. In EU countries, the
number of confirmed human campylobacteriosis cases was
236,851 in 2014, an increase of 22,067 cases (9.6 %) com-
pared to 2013 (EFSA and ECDC 2015). Mortality associated
with Campylobacter infections is relatively low, and no spe-
cific treatment is required for a vast majority of patients.
However, Campylobacter infections constitute a serious prob-
lem due to the high number of cases, severity of possible
neurological complications, as well as high social and eco-
nomic costs of the disease (Kaakoush et al. 2015;
Kirkpatrick and Tribble 2011).
The consumption of infected poultrymeat is amajor source of
infection. European Food Safety Authority (EFSA) reported that
in 2014, 38.4 % of the 6703 samples of fresh broiler meat were
found to be Campylobacter positive (EFSA and ECDC 2015).
Efforts to comply with EU hygiene and biosecurity regulations
appear insufficient to control or eliminate Campylobacter from
the poultry food chain (Havelaar et al. 2007;Mangen et al. 2007).
Elimination of Campylobacter jejuni from chickens would sig-
nificantly reduce the incidence of campylobacteriosis in humans
and seems to be an alternative and more realistic approach for
controlling Campylobacter contamination. However, anti-
Campylobacter chicken vaccines are not commercially avail-
able yet.
Many Gram-negative bacteria, especially pathogenic ones
(such as Neisseria meningitidis, Haemophilus influenzae,
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Helicobacter pylori, Borrelia burgdorferi, Pseudomonas
aeruginosa, Shewanella spp., Shigella spp., Salmonella spp.),
produce outer membrane vesicles (OMVs). Secretion of these
vesicles to a medium is a naturally occurring phenomenon.
Vesicles contain not only outer membrane-associated proteins
but also periplasmic and even cytoplasm-located molecules (vir-
ulence factors, DNA chains, enzymes) (Kuehn and Kesty 2005).
Considering their immunogenic and self-adjuvant properties,
the ability to be taken up by mammalian cells, and adjustability
of their content by recombinant engineering,OMVs are attractive
candidates for vaccine delivery vectors. Composition of the
OMVs (LPS, glycerophospholipids, OM and periplasmic pro-
teins) makes them capable of mediating both pro- and anti-
inflammatory activities leading to a clearance of infection or a
widespread inflammation (Mashburn-Warren et al. 2008;
Mashburn and Whiteley 2005). That is why OMVs are useful
as vaccines and adjuvants stimulating protective mucosal and
humoral immune responses (Collins 2011), already constituting
a base of several licensed vaccines and gaining an increasing
popularity (van der Pol et al. 2015). For example, conventional
wild-type outer membrane vesicle (wtOMV) vaccines are the
only formulations that have shown efficacy against serogroup
B meningococcal disease (Acevedo et al. 2014; Asensio et al.
2011; Holst et al. 2009; Roberts et al. 2008). Consequently, a
novel vaccine (4CMenB), against serogroup B meningococcal
disease, composed of protein antigens identified by reverse
vaccinology (fHBP fused to GNA2091, GNA2132 fused to
GNA1030, and NadA), combined with OMVs is now approved
in Europe, Canada, Australia, and some Latin American coun-
tries (Carter 2013; Giuliani et al. 2006; Martin and Snape 2013;
Serruto et al. 2010).
Campylobacter jejuniOMVs have not yet attracted a com-
parable interest. It has only been shown that C. jejuni mem-
brane vesicles contain a toxin-dubbed cytolethal distending
toxin (CDT) (Elmi et al. 2012; Lindmark et al. 2009), and
proteomic analyses ofC. jejuniOMVs identified 151 proteins,
including periplasmic, outer membrane associated, inner-
membrane, and even cytoplasmic ones. Among them, all three
subunits of CDT (CdtA, CdtB, and CdtC) and sixteen-
glycosylated proteins were present (Elmi et al. 2012; Jang
et al. 2014).
One of the latter is CjaA, an extracytoplasmic, glyco-
sylated and highly immunogenic protein cloned and char-
acterized in our laboratory (Pawelec et al. 1997;
Wyszynska et al. 2008). CjaA is conserved between dif-
ferent Campylobacter serotypes. Crystallographic analyses
of the Escherichia coli-produced rCjaA determined that CjaA
binds to the cysteine ligand and is a constituent of the ABC
cysteine transport system (Muller et al. 2005). Expression of
CjaA in bacteria cultured on solid media increases under iron
deficiency conditions and is higher in clinical Campylobacter
isolates than in laboratory strains (Cordwell et al. 2008;
Holmes et al. 2005; Shoaf-Sweeney et al. 2008). These facts
suggest that CjaA participates in a colonization process
in vivo.
CjaA is recognized by chicken maternal antibodies
(Cordwell et al. 2008; Shoaf-Sweeney et al. 2008), and
several groups attempted to utilize it as an antigen for
immunization of chickens. We were first to show that vacci-
nation with live S. enterica sv. Typhimurium χ3987-expressing
CjaA reduces the colonization with heterologous C. jejuni
strain by as much as six logs (Wyszynska et al. 2004). Oral
immunization of SPF birds with S. enterica sv. Typhimurium
aroA mutant producing CjaA antigen fused to the C-terminal
part of the fragment C of tetanus toxin resulted in about
1.4 log10 CFU/g reduction in the cecal load of C. jejuni
(Buckley et al. 2010). Similarly, Salmonella-mediated delivery
of the linear epitope of CjaA fused to the LamB protein and
coexpressed with the immuneenhancing CD154 ligand caused
approximately 2-log reduction in ileal load of C. jejuni (Layton
et al. 2011). Finally, oral inoculation of SPF chicken with
Eimeria tenella oocysts, modified to express CjaA on the sur-
face, induced 91 and 86 % immune protection against C. jejuni
challenge compared with unvaccinated and wild-type
E. tenella-vaccinated controls (Clark et al. 2012). All these
experiments demonstrated a promising, albeit not sufficient
protection; importantly, the effect was dependent also on chick-
en breeds used.
In this study, we employed yet another delivery mode and
evaluated the protective effect of a nonadjuvanted, multivalent
OMV vaccine administered in ovo against infection with
C. jejuni, employing natural OMVs as well as OMVs enriched
with CjaA due to the introduction of an extra copy of the wt
cjaA gene or C20A mutant of the cjaA known to shift the
protein localization into periplasm. Our work demonstrated
that the immunization of chickens with OMVs provides a
mean to reduce a cecal colonization with wt C. jejuni.
Materials and methods
Bacterial strains, media, and culture conditions
Bacterial strains and plasmids used in this study are listed in
Table 1.
Campylobacter jejuni strains were grown on Blood Agar
no. 2 (BA, Oxoid) plates supplemented with 5 % horse blood,
Campylobacter selective supplement (Blaser-Wang) (Oxoid,
Basingstoke, UK), and tetracycline (10 μg/ml) at 37 °C or
42 °C for 16–24 h under microaerobic conditions (6 % O2,
10 % CO2, 85 % N2). If necessary, plates were also supple-
mented with chloramphenicol (20 μg/ml) and/or kanamycine
(25 μg/ml). Campylobacter strains used for isolation OMVs
were grown inMueller–Hinton broth under microaerobic con-
ditions at 37 °C.
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Campylobacter jejuni 12/2 strain, isolated from an intesti-
nal tract of a chicken, labeled with the pUOA18 plasmid con-
taining cat gene, was utilized in challenge experiments.
Site-directed mutagenesis
Point mutation was generated using the QuikChange site-
directed mutagenesis kit according to procedures recommended
by the supplier (Stratagene). A derivative of pBluescript II SK,
containing the cjaA gene with its own promoter from C. jejuni
81176 pVir, was used as a template for PCR-mediated mutagen-
esis. Point mutation C20A was introduced with primers
CAGTAGTATTGGCTGCTGCTGGAGGAAATTCTGACTC-
TAAAAC and GTTTTAGAG TCAGAATTTCCTCCAGCAG
CAGCCAATACTACTG (mismatches are double underlined).
The plasmid containing the cjaA gene with C20A was
transformed into E. coli TG1, and a presence of the desired
mutation was verified by DNA sequencing. After digestion of
the resulting recombinant plasmid with NotI and SalI, the
fragment containing the cjaA gene was cloned into the shuttle
vector pRY111 digested with the same enzymes. The resulting
plasmid was named pUWM1405 (cjaAwith C20A mutation).
Shuttle plasmid containing a wild copy of the C. jejuni cjaA
gene was named pUWM639. All derivatives of pRY111 were
introduced into C. jejuni cjaA− by bi-parental conjugation
(Davis et al. 2008).
We had to recreate the C. jejuni 81176 cjaA− mutant.
The one used in our previous studies had lost pTet plasmid,
which could be important in conjugative transfer of plas-
mids. New mutant was constructed using standard natural
transformation assay (Vegge et al. 2012). Exponentially,
growing cells of C. jejuni 81176 TcR were transformed
with genomic DNA of C. jejuni 81176::CjaA−, TcS strain.
The disruption of cjaA gene was confirmed by PCR and
sequencing.
OMV purification and quantitation
OMVs were isolated from C. jejuni strain 81176 using methods
described by Elmi et al. (2012) and Chutkan et al. (2013).
Campylobacter jejuni 81176 strain was grown in the
Mueller–Hinton broth under microaerobic conditions at
37 °C. An overnight culture was diluted 1:100 into 330 ml
of fresh growth media and grown 16–18 h to a mid log phase.
Briefly, the cells were pelleted twice, using centrifugation at
6000×g for 2 × 20 min at 4 °C. Supernatants were filtered
through a 0.22-μm filter device to remove remaining cells.
The filtrate was ultracentrifuged in Beckman L7-55
Ultracentrifuge at 150,000×g for 3 h at 4 °C, using a 50.2 Ti
rotor. OMV preparations were plated on BA plates and incu-
bated under microaerobic conditions to confirm the absence of
viable bacteria.
The pellets were resuspended with Dulbecco’s phosphate-
buffered saline (DPBS) or PBS and stored at −20 °C until
needed. Before injecting into eggs, the OMV samples were
sterilized by filtration using Ultrafree-MC-GV Centrifugal fil-
ters (Merck Millipore). A protein content of OMVs was mea-
sured by BCA assay.
Enrichment of C. jejuni OMVs with the CjaA protein
Plasmid pUWM639, carrying an additional copy of cjaA gene on
the shuttle vector (pRY 111 plasmid), was introduced into 81176
C. jejuni cjaA− strain by standard bi-parental conjugation proce-
dure (with E. coli S17.1 strain) (Davis et al. 2008). Similarly,
pUWM1405, with C20A point mutation in cjaA gene, was in-
troduced into 81176 C. jejuni cjaA− to increase the CjaA content
in periplasm. The OMVs produced by C. jejuni 81176/
pUWM639 and C. jejuni 81176/pUWM1405 strains were puri-
fied as described above. The quantification of CjaA protein in
OMV from abovementioned strains was carried out using
enzyme-linked immunosorbent assay (ELISA). Serial dilutions
Table 1 Strains and plasmids




Wild type, human isolate Korlath et al. (1985)
81176 cjaA− pVir, cjaA::aphA3, TcR This study
12 (PCM 2852) Wild type; isolated from a chicken, good colonizer Wyszynska et al. (2004)
12/2 Wild type; isolated from a chicken with introduced
pUOA18 plasmid; good colonizer, CmR
(Wyszynska et al. 2004)
Escherichia coli
E. coli S17.1 F‾ recA thi pro hsdR− M+ RP4:2-Tc:Mu:Km Tn7 TpR
SmR λpir Tra+
Simon et al. (1983)
Plasmids
pUWM639 cjaA gene (from 81176) cloned into pRY111, CmR This study
pUWM1405 cjaA gene (from 81176) with C20A point mutation
cloned into pRY111, CmR
This study
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of total, heat-treated (100 °C for 20 min) OMVs were used to
coat 96-well plates. The recombinant CjaA antigen was used as
the plate-coating antigen for construction of a standard curve.
Coated wells were incubated with specific rabbit anti-rCjaA an-
tibodies and with alkaline phosphatase-conjugated second goat
anti-rabbit IgG antibodies (Sigma-Aldrich). The reaction was run
with p-nitrophenyl phosphate (1 mg/ml) as a substrate and was
stopped after 30-min incubation (room temperature) with 3.0-M
sodium hydroxide. Optical density was determined at 405 nm
using the ELISA reader (Tekan). Each sample was analyzed in
triplicate. The results were expressed relative to the standard
protein per milligram of total OMV protein.
Animal supply and housing
Animal experiments were performed using the Rosa1 breed of
chickens. This breed was created by crossing Sussex hen with
Rhode Island Red rooster. The birds were housed in separate
cages for each group and given water and food ad libitum. All
animal experiments were carried out with approval nr 397/
2012 of the LKE (First Local Ethical Committee on Animal
Testing in Warsaw).
Immunization and challenge regimen
One hundred sixty-four 18-day-old chick embryos of laying
hens (Rosa1 breed) were orally immunized by injection of
0.1-ml different OMVs (wtOMVs, 639-OMVs, 1405-
OMVs) into the amniotic fluid. Each injection dose contained
200 μg of protein. Groups of birds inoculated with PBS buffer
served as controls. Fourteen-day post-hatch half of all chicks
groups were orally challenged with 105-CFU of the live
C. jejuni 12/pUOA18 strain. Cloacal swabs were taken every
2 days after hatch to evaluate Campylobacter colonization of
birds. After the challenge, the C. jejuni present in chicken
cecal contents were enumerated by plating. On 21 and 28 days
after hatch, chicks were sacrificed, and their cecal contents
were aseptically removed. Samples were weighed and nine
times their weight of PBS was added. Samples were homog-
enized, and serially diluted. 0.1 ml of each dilution was plated
on Campylobacter BA plates, supplemented with chloram-
phenicol. The scheme of the protection experiment is shown
in Table 2.
Samples of intestinal content and blood were collected on
2, 7, 14, 21 and 28-day post-hatch as shown in Table 2. ELISA
test was performed to determine the level of C. jejuni-specific
immunoglobulin Y (IgY) antibodies and immunoglobulin A
(IgA) in serum and intestinal secretion samples.
ELISA for serum IgG antibodies and intestinal IgA
antibodies
The level of antibodies against C.jejuni protein in intestinal
secretions and sera of chicken was quantified by ELISA.
Ninety-six-well plates (Nunc, Thermo Scientific) were
coated overnight at 4 °C with whole-cell C. jejuni proteins
(20 μg/well), washed three times with PBS containing
0.02 % Tween 20 (Sigma-Aldrich), blocked for 1 h at 37 °C
with PBS containing 2 % bovine serum albumin (Sigma-
Aldrich), washed as described previously, and incubated for
1.5 h at room temperature with either diluted sera (1:300) or
intestinal secretion samples (1:10). The plates were developed
with 3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich), using
goat anti-chicken IgA horseradish peroxidase conjugate
(Thermo Scientific, Rockford, IL) or rabbit anti-chicken IgY
(whole molecule)-peroxidase (Sigma-Aldrich) (dilution
1:2000), respectively. The plates were incubated with the sub-
strate for 25 min at room temperature and then the colorimet-
ric reaction was stopped by adding 2-M H2SO4 (Sigma-
Aldrich). Absorbance was measured at 490 nm using an
ELISA reader (Tekan). Each sample was analyzed in
duplicate.
Statistical analyses
All statistical analyses of the colonization results were per-
formed using GraphPad Prism 6 (GraphPad Software, San
Diego, CA) or STATISTICA 10PL software (StatSoft,
USA). The significance of differences between the obtained
values was appraised using one-way analysis of variance
(ANOVA), followed by the post-hoc Tukey’s tests.
Statistical analyses of ELISA test were assessed using multi-
factorial (two-way) ANOVA nested for duplicates and
Scheffe’s post-hoc test or the Kruskal–Wallis test followed
by Dunn’s multiple comparison post-hoc test. Any p values
<0.05 were considered significant.
Table 2 Scheme of immune
response and protection
experiments
Week of life −1 0 1 2 3 4
Immunization with OMVs +
Collection of gut secretion and blood samples for immune response analysis + + + + +
Challenge with Campylobacter +
Cecum isolation for Campylobacter enumeration + +
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Results
Enrichment of C. jejuni OMVs with the CjaA protein
We decided to utilize OMVs for in ovo immunization of
chickens, additionally attempting to enrich OMVs with extra
CjaA in order to increase the load of the antigen in the vaccine.
Two strategies were employed toward this goal. The first one
relied on expressing an additional copy of the complete cjaA
gene introduced into the multicopy plasmid shuttle vector
pRY111 (Yao et al. 1993). The constructed plasmid was
named pUWM639. Since cjaA expression from pUWM639
was driven by its own strong promoter, it seemed plausible
that this manipulation would increase the content of CjaA
protein inside the cells and within OMVs. The second strategy
took advantage of the fact that CjaA in Campylobacter cells
localizes mainly in the inner membrane (IM). We had previ-
ously created a Campylobacter coli 72Dz/92 strain with the
C20A (cysteine into alanine) point mutation in the CjaA signal
sequence. Lack of this cysteine shifted the location of the
protein from inner membrane to periplasm (Wyszynska et al.
2008). We expected that the periplasmic location of CjaAwill
further increase the quantity of this protein in OMVs. Toward
this end, the pUWM1405 plasmidwas prepared that contained
the C20A cjaA mutant introduced into pRY111.
Both pUWM639 and pUWM1405 plasmids were intro-
duced into C. jejuni 81176 cjaA− strain via conjugation. To
ensure an easy detection of the introduced gene expression,
the host strain had been previously deprived of endogenous
CjaA protein by means of a gene knockout. Western blot
experiments with specific rabbit anti-rCjaA antibodies
showed a high level of protein production (Fig. S1,
supplementary materials).
ELISA assay of the CjaA protein in OMVs isolated from
wt strain and 81176 C. jejuni strains harboring pUWM639,
and pUWM1405 plasmids demonstrated that OMVs pro-
duced by modified strains harbored much higher a content
of CjaA antigen than wt OMVs. The results are shown in
Fig. 1.
Immunization procedure. Antibody immune response
in vaccinated chickens
A multiantigenic nature of an OMV vaccine may enhance
specific humoral immune response to provide protection
against C. jejuni strains. Therefore, the antibody response of
chicks to OMVs delivered in ovo was analyzed. Eighteen-
day-old embryos were divided into four groups (one control
and three treatment groups) and orally immunized by OMVs
injection into an amniotic fluid. The control group received
sterile PBS. The treatment groups were immunized with
wtOMV, 639-OMV, or 1405-OMV. Several experimental
studies have shown that in commercial flocks, chicks are
colonized by C. jejuni around second or third week of life
(Conlan et al. 2007). Therefore, 2 weeks after hatching, half
of the chicks from each group were challenged with 105 bac-
terial cells of a chicken-isolated C. jejuni strain. Serum IgY
and mucosal IgA antibody responses against Campylobacter
proteins were measured by ELISA assay using the whole-cell
lysate as a coating antigen. Analysis of serum samples obtain-
ed from 1-, 7- to 14-day-old chicks showed relatively high
levels of specific IgY in all groups, which dramatically de-
creased by week 2. Starting at 1 week after challenge, anti-
Campylobacter IgY antibody level consistently increased in
all experimental groups (data not shown). IgY antibody titers
did not differ significantly among the four experimental
groups at any of the time points (Kruskal–Wallis test).
Analysis of the intestinal samples also showed an induction
of specific mucosal anti-Campylobacter IgA antibodies
(Fig. 2). We observed an increasing level of IgA antibody
2 weeks after challenge (28 days of life), but the differences
again were not statistically significant.
Multifactorial (two-way) ANOVA nested for duplicates of
ELISA measurement indicated that IgA levels in challenged
animals significantly correlated with time and OMVs type
Fig. 1 Comparison of protein CjaA content in different types of OMVs.
CjaA in wtOMV was marked as 100 %. The quantification of CjaA
protein in OMV-639, OMV-1405, and wtOMV was carried out using
ELISA assay. Serial dilutions of total OMVs were used to coat 96-well
plates. The recombinant CjaA antigen was used as the plate-coating an-
tigen for construction of a standard curve. Coated wells were incubated
with specific rabbit anti-rCjaA antibodies and with alkaline phosphatase-
conjugated second goat anti-rabbit IgG antibodies. Each sample was an-
alyzed in triplicate. The results were expressed relative to the standard
protein per milligram of total OMV protein. A statistical analysis was
carried out using multifactorial (one-way) ANOVA followed by
Tukey’s multiple comparisons test. Asterisks indicate significant differ-
ences (p < 0.05) between analyzed groups and the control group
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(p < 0.00001 and p < 0.0009, respectively), and there was also
a significant interaction of time and OMV type (p < 0.004).
Overall, there was a very significant increase of IgA at day 28
(p < 0.000001) and a slight decrease at day 14 compared to
day 7 (p = 0.024; Scheffe’s post-hoc tests). Overexpression of
a C20Amutant of CjaAwas the onlymanipulation significant-
ly affecting IgA level, leading to a slight increase in compar-
ison to PBS and wt treatment (p < 0.02 and p < 0.004, respec-
tively, Scheffe’s post-hoc test) in univariate analysis; for inter-
actions, expression of a C20A mutant led to a very significant
increase of IgA at day 28 comparing to most other combina-
tions, other changes were nonsignificant or meaningless at
best.
Protective efficacy of OMVs in ovo immunization
of chickens
Three different types of OMVs, namely wtOMVs, 639-
OMVs, and 1405-OMVs were tested for protective effect in
Rosa1 chickens. In this study, 18-day-old chicken embryos
were in ovo vaccinated with a single dose of OMVs vaccine
by oral routes and challenged 2 weeks after hatch with the
heterologous wild-type strain marked by plasmid pUOA18.
As shown in Fig. 3, the in ovo immunization with 105-CFU/
ml of C. jejuni strain (12/2) provided a moderate protection
against Campylobacter infection at the seventh day after chal-
lenge in two vaccinated groups (wtOMV and 639-OMV,
p < 0.05). Our results indicated that mean colonization levels
were of 2 × 109 CFU in control group and from ∼9 × 107 in
639-OMV group to 3 × 108 in wtOMV and 1405-OMV
groups. Two weeks after challenge, the colonization level of
immunized bird’s ceca was still lower than nonimmunized
bird’s ceca, but the results for immunized groups were not
statistically significant (Fig. 3).
Multifactorial (two-way) ANOVA on log-transformed
CFU data demonstrated that both the time from the challenge
and the type of OMVs were independently correlating to col-
onization level (p < 004 and p < 0.007, respectively). The
impact of time indicates an increasing level of infection after
2 weeks compared to 1-week post-challenge. The impact of
vaccination with OMVs was further analyzed post-hoc using
Tukey’s test, revealing that OMVs from wt strain or strain
overexpressing wtCjaA confer significant protection.
There was no indication of significant interactions between
the time from the challenge and the type of OMV used
(p > 0.44).
Discussion
Diverse strategies have been applied to produce an effective
anti-Campylobacter vaccine for chickens. The greatest prog-
ress has been made in the development of subunit vaccines
composed of Campylobacter proteins, whether delivered di-
rectly or by vectors such as live-attenuated Salmonella cells
expressing Campylobacter antigens (Buckley et al. 2010;
Fig. 2 Mean anti-Campylobacter-specific mucosal IgA levels measured
by ELISA at the time intervals on the x-axis. Various types of OMVswere
administred in ovo to 18-day-old chickens embryos. Intestinal samples
(ceca) were collected, when birds were 1, 2, 3, and 4 weeks old.
Campylobacter whole-cell lysates were used as coating antigens.
Intestinal secretion samples were diluted 1:10. Error bars indicate stan-
dard error of the mean. Statistical analyses of ELISA test were assessed
using multifactorial (two-way) ANOVA followed Scheffe’s post-hoc test.
Statistical analyses were performed using STATISTICA 10PL software
(StatSoft, USA). Any p values <0.05 were considered significant
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Layton et al. 2011;Wyszynska et al. 2004). However, the real-
life results of their usage are mediocre at best, and new ap-
proaches are clearly needed.
The major goal of this study was, therefore, to analyze the
potential of OMVs derived from C. jejuni as a new vaccine
compound. Here, for the first time, we combined OMVs as a
carrier of antigens with in ovo vaccination as a delivery mode
to obtain an alternative method for post-hatch immunization
of chickens against C. jejuni.
In ovo antigen delivery stimulates both innate and adaptive
immune responses and can be used for vaccination (especially
against viral diseases), for beneficial modification of the bac-
terial profile in the colon of chickens, for stimulation of an
immunological response and embryonic development, and for
testing of teratogenic effects (Bande et al. 2015; Negash et al.
2004; Toro et al. 2007).
The avian immune system begins to develop early during
embryogenesis, and antibody responses to antigens could be
induced in 12-to-14-day-old chicken embryos (Sharma 1999).
However, a full immunocompetence normally builds up only
after few days of post-hatching (Mast and Goddeeris 1999).
Earlier on, the immune defense is provided by maternal anti-
bodies, which had been transferred from a hen to offsprings
through egg yolk. Thus, the few days after hatching are cru-
cial: chicks become exposed to environmental threats but are
no longer supplemented with new maternal antibodies. And
although the gut-associated lymphoid tissue (GALT), which
provides an important enteric protection, matures functionally
around fourth day after hatching, the secretory IgA response
against enteric antigens mounts slowly, completing toward the
end of the second week of age (Bar-Shira et al. 2003).
The in ovo vaccination can fill this gap, generating immu-
nity as early as possible, even by the time of hatch.
In order to further improve the in ovo vaccination, we have
established and employed a simple way to enrich OMVs with
the CjaA antigen based on simple recombinant DNA tech-
niques. We believe that this method is applicable to many
other antigens.
Since the protective role of antibodies is regarded as a key
factor in the development of poultry vaccines against
Campylobacter, we investigated the IgY and IgA levels in
chicken from control and immunized groups. Our results are
consistent with earlier reports. Sera of chickens contained
large quantities of maternal IgY during the first week of life,
which decreased gradually during next 2 weeks and resumed
to rise after a colonization of the intestinal tract by C. jejuni.
However, IgY antibodies play little role in the clearance of
C. jejuni from cecum, a decrease in the number of C. jejuni
organisms colonizing the intestinal tract has been observed
(Newell and Fearnley 2003; Sahin et al. 2003; Shoaf-
Sweeney et al. 2008).
Mucosal IgA is responsible for preventing entry of com-
mensal bacteria into subepithelial areas by blocking their ad-
hesion to epithelial cells or by returning those bacteria that
have already penetrated to the basolateral site, without
eliciting an inflammatory response (Brisbin et al. 2008).
Fig. 3 Colonization of chickens vaccinated with C. jejuni OMVs:
wtOMV, 639-OMV, and 1405-OMVafter C. jejuni challenge. Eighteen-
day-old chicken embryos were given one dose of OMVs and 2 weeks
after hatching was challenged with C. jejuni 12/2. Control birds were
given PBS. Viable C. jejuni cells were recovered from the ceca of
chickens 7 and 14 days post-infection (d.p.i.). Bacterial recoveries
represent colonization levels of five or six birds per time interval. A
geometric mean for each group is denoted by a bar. A statistical analysis
was carried out using multifactorial (two-way) ANOVA followed by
Tukey’s multiple comparisons test. Asterisks indicate significant differ-
ences (p < 0.05) between analyzed groups and the control group
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They probably play an important role in redirecting inflam-
matory response toward tolerance. As in the case of IgY, we
observed increasing levels of IgA antibodies starting at 1 week
after C. jejuni challenge, which proves that Campylobacter
challenge triggers birds immune response. In both experi-
ments, the level of mucosal IgA and IgY in serum of nonin-
fected was lower compared to colonized chicken.
Immunization with wtOMVs and OMVs enriched in the
CjaA antigen had a significant effect on the cecal load of
C. jejuni 7 days after challenge, when compared to vaccination
with control preparation. Fourteen days after challenge, the
C. jejuni cecal loadswere still reduced; however, the differences
were not statistically significant anymore. It is puzzling why the
periplasmic mutant of CjaA (1405) failed to confer a protection
comparable to ones obtained with OMVs from wt and 639
strains. We have verified (Fig. 1) that the expression of this
mutant in OMVs was actually higher than wt protein (albeit
lower than overexpressed wt protein). This result was obtained
using ELISAwith polyvalent anti-CjaA rabbit serum. It is pos-
sible that the membrane protein, forcefully relocated (released)
to periplasm, does not retain (or does not achieve) its normal
conformation and/or modifications. Regarding the latter, this
mutant remains to appear as a double band on western blotting,
which is demonstrated to reflect the glycosylation that it is
normally subjected to (Wyszynska et al. 2008). However, this
does not preclude that the glycosylation is incomplete/atypical
or that the protein is otherwise altered, thus having a distorted
antigenicity. As a result, it would be less efficiently detected in
ELISA by a polyvalent serum raised against wt protein (leading
to false impression of ‘decreased’ level comparing to
overexpressed wt protein), but more importantly, it would elicit
an immune response shifted toward ‘false’ antigens, thus offer-
ing decreased protection against wt strains presenting only a
typical wt CjaA. This explanation remains speculative as it
was not further investigated.
Thus, a single vaccination regime for 18-day-old embryos
has induced a protection against C. jejuni challenge, but the
protection was too short lived. Efforts should be undertaken to
enhance OMV vaccine efficacy by combining OMV with
appropriate adjuvants or additional protein antigens like in
4CMenB in anti-N. meningitidis vaccine (Carter 2013;
Martin and Snape 2013). Nevertheless, most of the recently
tested vaccines required two doses for a full protection. Thus,
the additional dose of a vaccine administrated after hatch may
still be needed.
The time and route of administration of such a second dose
deserve consideration. Presumably, the booster dose should be
given when the defense system is well developed, which is
about 7 days after hatch (Mast and Goddeeris 1999).
Regarding the route, in ovo vaccines are typically injected
into the amniotic sac. The embryo then swallows and ingests
surrounding amnion fluid containing vaccine antigens.
Antigens subsequently pass into the intestine, where they
can stimulate the immunocompetent cells of GALT
(Jochemsen and Jeurissen 2002).
Orally administrated vaccine must, therefore, survive a pas-
sage through the crop and stomach into the intestine. Protein
antigens combined with OMV vaccines may thus benefit from
an additional protection, e.g., liposome encapsulation.
It is not certain whether the booster should follow the same
route. Several studies have tested various administration
routes of OMV vaccines in other animals. Schild et al.
(2008) immunized mice with OMVs derived from Vibrio
cholerae via three routes (intranasal, intragastric, and intraper-
itoneal). Interestingly, all the routes studied had comparably
strong effect on Ig titers (IgG1, IgG2, IgM, and IgA were
studied) and provided comparable protection against
V. cholerae infection and colonization. The intranasal and
intragastric immunized mice were fully protected, and from
intraperitoneal immunized mice, at least 10,000-fold lower
numbers of Vibrio CFU were recovered than in the infection
of naïve animals. Nieves et al. (2011) demonstrated that a
subcutaneous immunization with OMVs isolated from
Burkholderia pseudomallei provides a significant protection
against lethal B. pseudomallei infection in BALB/c mice.
Thus, the oral route for booster in chicken may be preferred
as the simplest one, but further studies are needed to verify and
compare its efficacy to other modes of delivery.
In conclusion, we presented a proof-of-concept study on
the usability of C. jejuni OMVs enriched with CjaA anti-
gen as an in ovo protective vaccine against C. jejuni in
chickens. While the response after single dose of a vaccine
is clearly observable, the effect was rather short lived.
Further studies on booster dosing and/or immunoadjuvant
support are required.
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